Robert Joseph March Sells 4,775 Shares of BioSyent Inc. (CVE:RX) Stock

BioSyent Inc. (CVE:RX) Senior Officer Robert Joseph March sold 4,775 shares of BioSyent stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of C$11.65, for a total value of C$55,628.75.

BioSyent Trading Up 3.2 %

Shares of BioSyent stock opened at C$11.98 on Friday. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. BioSyent Inc. has a 1 year low of C$8.24 and a 1 year high of C$11.98. The company has a market capitalization of C$138.85 million, a P/E ratio of 19.97 and a beta of 0.93. The business has a 50 day moving average price of C$11.21 and a 200 day moving average price of C$10.53.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.